Skip to main content

Advertisement

SpringerLink
Log in

Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine

  • Case Report
  • Published:
CEN Case Reports Aims and scope Submit manuscript

Abstract

A 42-year-old man with end-stage renal failure had been receiving hemodialysis therapy since April 2009. Initially, darbepoetin alfa was administered to treat his renal anemia. After treatment was switched to epoetin beta pegol, the patient’s hemoglobin levels rapidly decreased. He was diagnosed with pure red cell aplasia (PRCA) based on the results of a bone marrow examination. Epoetin beta pegol was strongly suspected to be the cause of the PRCA, and although he tested negative for anti-epoetin beta pegol antibodies, epoetin beta pegol was discontinued and cyclosporine therapy was initiated. Thereafter, his hemoglobin levels increased, and his anemia dramatically improved after 3 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Cazzola M, Mercuriali F, Brugnara C. Use of recombinant human erythropoietin outside the setting of uremia. Blood. 1997;89:4248–67.

    CAS  PubMed  Google Scholar 

  2. Curran MP, McCormack PL. Methoxy polyethylene glycol-epoetin beta: a review of its use in the management of anaemia associated with chronic kidney disease. Drugs. 2008;68:1139–56.

    Article  CAS  PubMed  Google Scholar 

  3. Casadevall N, Nataf J, Viron B, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med. 2002;346:469–75.

    Article  CAS  PubMed  Google Scholar 

  4. Shinohara K, Mitani N, Miyazaki M, et al. Pure red-cell aplasia caused by the antibody to recombinant erythropoietin, epoetin-beta, in a Japanese patient with chronic renal failure. Am J Hematol. 2005;78:15–20.

    Article  PubMed  Google Scholar 

  5. Katagiri D, Shibata M, Katsuki T, et al. Antiepoetin antibody-related pure red cell aplasia: successful remission with cessation of recombinant erythropoietin alone. Clin Exp Nephrol. 2010;14:501–5.

    Article  PubMed  Google Scholar 

  6. Kidney Disease Improving Global Outcomes. (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279–335.

    Article  Google Scholar 

  7. Thorpe R, Swanson SJ. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant 2005;20:iv16–22.

  8. Sawada K, Hirokawa M, Fujishima N, et al. Long-term outcome of patients with acquired primary idiopathic pure red cell aplasia receiving cyclosporine A. Haematologica. 2007;92:1021–8.

    Article  CAS  PubMed  Google Scholar 

  9. Omine M. Overview of the clinical reference guides for the idiopathic hematopoietic disorders. Nihon Rinsho. 2008;66:433–8.

    PubMed  Google Scholar 

  10. Tanuma Y, Yokoo A, Takashima H. Acquired pure red cell aplasia in a hemodialyzed patient. Int J Urol. 2003;10:550–3.

    Article  PubMed  Google Scholar 

  11. Miyazaki T, Obana T, Takasaki H, et al. Pure red cell aplasia in patients treated with recombinant erythropoietin for anemia due to chronic renal disease. Rinsho Ketsueki. 2007;48:391–6.

    PubMed  Google Scholar 

  12. Fisch P, Handgretinger R, Schaefer HE. Pure red cell aplasia. Br J Haematol. 2000;111:1010–22.

    Article  CAS  PubMed  Google Scholar 

  13. Elliott S, Pham E, Macdougall IC. Erythropoietins: a common mechanism of action. Exp Hematol. 2008;36:1573–84.

    Article  CAS  PubMed  Google Scholar 

  14. Wang YJ, Hao SJ, Liu YD, et al. PEGylation markedly enhances the in vivo potency of recombinant human non-glycosylated erythropoietin: a comparison with glycosylated erythropoietin. J Control Release. 2010;145:306–13.

    Article  CAS  PubMed  Google Scholar 

  15. Jevsevar S, Kunstelj M, Porekar VG. PEGylation of therapeutic proteins. Biotechnol J. 2010;5:113–28.

    Article  CAS  PubMed  Google Scholar 

  16. Chang CS, Yan SL, Lin HY, Yu FL, Tsai CY. Pure red cell aplasia caused by pegylated interferon-α-2a plus ribavirin in the treatment of chronic hepatitis C. World J Gastroenterol. 2011;17:2155–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Miura Y, Kami M, Yotsuya R, Toda N, Komatsu T. Pure red-cell aplasia associated with pegylated interferon-alpha-2b plus ribavirin. Am J Hematol. 2008;83:758–9.

    Article  PubMed  Google Scholar 

  18. Arcasoy MO, Rockey DC, Heneghan MA. Pure red cell aplasia following pegylated interferon alpha treatment. Am J Med. 2004;117:619–20.

    Article  PubMed  Google Scholar 

  19. Richter AW, Akerblom E. Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol. 1983;70:124–31.

    Article  CAS  PubMed  Google Scholar 

  20. Weaver EA, Barry MA. Effects of shielding adenoviral vectors with polyethylene glycol (PEG) on vector-specific and vaccine-mediated immune responses. Hum Gene Ther. 2008;19:1369–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Bennett CL, Cournoyer D, Carson KR, et al. Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood. 2005;106:3343–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Verhelst D, Rosser J, Casadevall N, Krüger A, Eckardt KU, Macdougall IC. Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet. 2004;363:1768–71.

    Article  CAS  PubMed  Google Scholar 

  23. Sawada K, Fujishima N, Hirokawa M. Acquired pure red cell aplasia: updated review of treatment. Br J Haematol. 2008;142:505–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Blume H, Donath F, Warnke A, Schug BS. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf. 2006;29:769–84.

    Article  CAS  PubMed  Google Scholar 

  25. Touchette MA, Slaughter RL. The effect of renal failure on hepatic drug clearance. DICP. 1991;25:1214–24.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are deeply grateful to Chugai Pharmaceutical Co. Ltd Kamakura Research Laboratories for anti-epoetin beta pegol antibody measurements.

Author information

Authors and Affiliations

  1. Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, 1-847 Amanuma-cho, Omiya-ku, Saitama, Saitama, 330-8503, Japan

    Keiji Hirai, Susumu Ookawara, Haruhisa Miyazawa, Kiyonori Ito, Yuichiro Ueda, Yoshio Kaku, Taro Hoshino, Izumi Yoshida, Yoshiyuki Morishita & Kaoru Tabei

  2. Division of Hematology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan

    Shun-ichi Kimura

  3. Kakuta Clinic, Saitama, Japan

    Sachiko Kakuta

Authors
  1. Keiji Hirai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susumu Ookawara
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haruhisa Miyazawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kiyonori Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuichiro Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshio Kaku
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Taro Hoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Shun-ichi Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Izumi Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sachiko Kakuta
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yoshiyuki Morishita
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kaoru Tabei
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susumu Ookawara.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hirai, K., Ookawara, S., Miyazawa, H. et al. Successful treatment of a hemodialyzed patient with pure red cell aplasia associated with epoetin beta pegol therapy with cyclosporine. CEN Case Rep 5, 78–82 (2016). https://doi.org/10.1007/s13730-015-0196-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13730-015-0196-8

Keywords

Search

Navigation